Educating Pharmacists on the Risks of Strong Opioids With Descriptive and Simulated Experience Risk Formats: A Randomized Controlled Trial

Abstract

Objectives. High opioid prescription rates in the United States and Europe suggest miscalibrated risk perceptions among those who prescribe, dispense, and take opioids. Findings from cognitive decision science suggest that risk perceptions and behaviors can differ depending on whether people learn about risks by experience or description. This study investigated effects of a descriptive versus an experience-based risk education format on pharmacists’ risk perceptions and counseling behavior in the long-term administration of strong opioids to patients with chronic noncancer pain. Methods. In an exploratory, randomized controlled online trial, 300 German pharmacists were randomly assigned to either a descriptive format (fact box) or a simulated experience format (interactive simulation). Primary Outcome Measures. 1) Objective risk perception, 2) subjective risk perception, and 3) intended and 4) actual counseling behavior. Results. Both risk formats significantly improved pharmacists’ objective risk perception, but pharmacists exposed to the fact box estimated the benefit-harm ratio more accurately than those exposed to the simulation. Both formats proved equally effective in adjusting pharmacists’ subjective risk perception toward a better recognition of opioids’ harms; however, pharmacists receiving the simulation showed a greater change in their actual counseling behavior and higher consistency between their intended and actual counseling than pharmacists receiving the fact box. Conclusion. The simulated experience format was less effective than the descriptive format in improving pharmacists’ objective risk perception, equally effective in motivating pharmacists to counsel patients on less risky treatment alternatives and more effective in changing the reported actual counseling behavior. Implications. These exploratory findings provide important insights into the relevance of the description-experience gap for drug safety and raise questions for future research regarding the specific mechanisms at work.

Developing principles for sharing information about potential trial intervention benefits and harms with patients: report of a modified Delphi survey

“…However, Drug Facts Boxes apply exclusively to the pharmaceutical setting and are not directly applicable to the UK regulatory research context. Relatedly, one study found that pharmacists changed the treatments they provided to patients depending on how risks were communicated to them [ 20 ]. A recent systematic review also found that there was not yet a clear, optimal method for communicating risks to patients within trials [ 21 ].…”

The Future of Decisions From Experience: Connecting Real-World Decision Problems to Cognitive Processes

“…Decisions involving health, including decisions about whether to smoke or not, which vaccines to take, and which disease screenings to undertake, are affected by past experiences, just as financial and environmental decisions are ( Betsch et al, 2011 ; Wegier et al, 2019 ; Wegier & Shaffer, 2017 ; Wegwarth et al, 2021 ). When health declines, people must decide between various medication and treatment options with different possible outcomes, including taking into account any potential side effects.…”